Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06119217 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

A Phase 2 study of Pancreatic Cancer, sponsored by Trishula Therapeutics.

Active
Registry status
Phase 2
Development phase
194
Enrollment target
20
Study locations

NCT06119217 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by Trishula Therapeutics. The registered enrollment target is 194 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06119217, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Trishula Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
194 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.

Conditions Studied

Pancreatic Cancer

Interventions

  • COMBINATION_PRODUCT TTX-030, nab-paclitaxel and gemcitabine
  • COMBINATION_PRODUCT TTX-030, budigalimab, nab-paclitaxel and gemcitabine
  • COMBINATION_PRODUCT Nab-Paclitaxel and gemcitabine

Study Locations (20)

California

  • Investigative Site - Bakersfield
  • Investigative Site - Fullerton
  • Investigative Site - Los Angeles

Florida

  • Investigative Site - St. Petersburg
  • Investigative Site - West Palm Beach

Oregon

  • Investigative Site - Eugene
  • Investigative Site - Portland

Arizona

  • Investigative Site - Tucson

Arkansas

  • Investigative SIte - Hot Springs

Colorado

  • Investigative Site - Denver

Georgia

  • Investigative Site - Atlanta

Kansas

  • Investigative Site - Wichita

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2024-03-25
Est. Completion 2027-06
Phase Phase 2

Sponsor

Trishula Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06119217

The ClinicalTrials.gov registry entry for NCT06119217 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (51% lower). The listed sponsor is Trishula Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which TTX-030, nab-paclitaxel and gemcitabine is the first listed.

NCT06119217 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Oregon.

Frequently Asked Questions

What is clinical trial NCT06119217 about?

NCT06119217 is a clinical study titled "Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients". This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metasta...

What is the current status of trial NCT06119217?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2024-03-25. Estimated completion is 2027-06.

What conditions does trial NCT06119217 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT06119217?

The interventions under investigation include: TTX-030, nab-paclitaxel and gemcitabine (COMBINATION_PRODUCT), TTX-030, budigalimab, nab-paclitaxel and gemcitabine (COMBINATION_PRODUCT), Nab-Paclitaxel and gemcitabine (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06119217?

This trial is sponsored by Trishula Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06119217 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.